On September 10, 2019 UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, reported that it will host an Investor Day on September 24, 2019 in New York where the Company will share updates on its clinical programs and launch readiness plans for UGN-101 (mitomycin gel) for instillation, its lead product candidate for the treatment of patients with low-grade upper tract urothelial cancer (LG UTUC) (Press release, UroGen Pharma, SEP 10, 2019, View Source [SID1234539414]). The program will also highlight the Company’s vision and strategy and include a panel discussion with key opinion leaders on the treatment of LG UTUC and low-grade non-muscle invasive bladder cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The live audio webcast and accompanying slide presentation will begin at 10:00AM Eastern Time. The live audio webcast can be accessed through the Events and Presentations section under the Investors tab of UroGen’s website at www.urogen.com. Following the live audio webcast, a replay will be available on UroGen’s website for approximately 30 days.
Management will also present at two investor conferences in September:
H.C. Wainwright 21st Annual Global Investment Conference
Tuesday, September 10th
10:50AM Eastern Time
New York, NY
Ladenburg Thalmann Healthcare Conference
Tuesday, September 24th
3:00PM Eastern Time
New York, NY
A live audio webcast of each event will be available on the Investors section of UroGen’s website, www.urogen.com. A replay of each webcast will be available on the website for approximately two weeks.